Alkermes plc (ALKS) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
17.47
↓-24% vs avg
5yr avg: 23.07
30Y Low8.3·High60.8
P/FCF
↓
12.41
↓-43% vs avg
5yr avg: 21.66
30Y Low9.8·High153.3
P/B Ratio
↓
3.28
-5% vs avg
5yr avg: 3.46
30Y Low1.6·High76.5
ROE
↑
14.7%
↓+34% vs avg
5yr avg: 11.0%
30Y Low-130%·High58%
Debt/EBITDA
↓
0.25
↓-86% vs avg
5yr avg: 1.76
30Y Low0.2·High32.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ALKS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Alkermes plc trades at 24.7x earnings, 61% above its 5-year average of 15.3x, sitting at the 71st percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 11%. On a free-cash-flow basis, the stock trades at 12.4x P/FCF, 43% below the 5-year average of 21.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.0B | $4.7B | $4.9B | $4.7B | $4.3B | $3.7B | $3.2B | $3.2B | $4.6B | $8.4B | $8.4B |
| Enterprise Value | $4.9B | $3.7B | $4.7B | $4.6B | $4.4B | $3.8B | $3.3B | $3.3B | $4.6B | $8.5B | $8.5B |
| P/E Ratio → | 24.70 | 19.57 | 13.25 | 13.21 | — | — | — | — | — | — | — |
| P/S Ratio | 4.04 | 3.20 | 3.12 | 2.83 | 3.85 | 3.19 | 3.05 | 2.74 | 4.18 | 9.29 | 11.29 |
| P/B Ratio | 3.28 | 2.60 | 3.32 | 3.91 | 4.10 | 3.36 | 2.97 | 2.95 | 3.91 | 6.98 | 6.96 |
| P/FCF | 12.41 | 9.83 | 12.00 | 13.33 | — | 51.50 | 77.99 | — | 153.35 | — | — |
| P/OCF | 11.44 | 9.07 | 11.08 | 11.73 | 203.32 | 36.80 | 38.24 | 44.45 | 46.11 | 437.54 | — |
P/E links to full P/E history page with 30-year chart
ALKS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Alkermes plc's enterprise value stands at 17.5x EBITDA, 24% below its 5-year average of 23.1x. The Healthcare sector median is 14.1x, placing the stock at a 24% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.49 | 2.99 | 2.78 | 3.93 | 3.26 | 3.18 | 2.81 | 4.19 | 9.39 | 11.42 |
| EV / EBITDA | 17.47 | 13.06 | 10.35 | 9.45 | 60.82 | 21.67 | — | — | 1012.78 | — | — |
| EV / EBIT | 19.33 | 12.09 | 9.97 | 10.40 | — | 38.63 | — | — | — | — | — |
| EV / FCF | — | 7.64 | 11.46 | 13.09 | — | 52.58 | 81.37 | — | 153.77 | — | — |
ALKS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Alkermes plc earns an operating margin of 17.2%. Operating margins have compressed from 24.9% to 17.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 14.7% is modest. ROIC of 18.9% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.3% | 86.3% | 84.2% | 84.8% | 80.4% | 83.2% | 82.8% | 84.6% | 83.9% | 82.9% | 82.3% |
| Operating Margin | 17.2% | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% | -10.8% | -15.0% | -9.1% | -16.4% | -28.0% |
| Net Profit Margin | 16.4% | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% | -16.8% | -12.7% | -17.5% | -28.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 14.7% | 14.7% | 27.5% | 31.7% | -14.7% | -4.4% | -10.3% | -17.4% | -11.7% | -13.1% | -16.5% |
| ROA | 10.5% | 10.5% | 17.5% | 17.4% | -7.9% | -2.4% | -5.9% | -10.8% | -7.7% | -9.0% | -11.6% |
| ROIC | 18.9% | 18.9% | 26.7% | 27.6% | -0.4% | 6.1% | -7.1% | -11.2% | -6.0% | -8.5% | -11.2% |
| ROCE | 14.2% | 14.2% | 26.2% | 26.9% | -0.4% | 6.4% | -7.7% | -12.1% | -6.6% | -9.8% | -13.3% |
ALKS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Alkermes plc carries a Debt/EBITDA ratio of 0.2x, which is very conservative (92% below the sector average of 3.1x). The company holds a net cash position — cash of $1.1B exceeds total debt of $70M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 24.7x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.05 | 0.31 | 0.36 | 0.37 | 0.38 | 0.27 | 0.24 | 0.23 | 0.23 |
| Debt / EBITDA | 0.25 | 0.25 | 0.17 | 0.76 | 5.29 | 2.36 | — | — | 61.63 | — | — |
| Net Debt / Equity | — | -0.58 | -0.15 | -0.07 | 0.08 | 0.07 | 0.13 | 0.08 | 0.01 | 0.07 | 0.08 |
| Net Debt / EBITDA | -3.73 | -3.73 | -0.48 | -0.17 | 1.21 | 0.45 | — | — | 2.77 | — | — |
| Debt / FCF | — | -2.19 | -0.53 | -0.24 | — | 1.08 | 3.38 | — | 0.42 | — | — |
| Interest Coverage | 24.74 | 24.74 | 20.65 | 19.30 | -1.39 | 8.82 | -10.15 | -13.49 | -7.22 | -10.93 | -13.40 |
Net cash position: cash ($1.1B) exceeds total debt ($70M)
ALKS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Alkermes plc's current ratio of 3.55x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.19x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.86x to 3.55x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.55 | 3.55 | 3.04 | 2.86 | 2.27 | 2.25 | 2.53 | 2.46 | 2.89 | 3.32 | 4.30 |
| Quick Ratio | 3.19 | 3.19 | 2.65 | 2.50 | 1.91 | 1.93 | 2.25 | 2.20 | 2.63 | 3.00 | 4.01 |
| Cash Ratio | 2.43 | 2.43 | 1.62 | 1.49 | 1.22 | 1.14 | 1.45 | 1.37 | 1.59 | 1.49 | 2.35 |
| Asset Turnover | — | 0.58 | 0.76 | 0.78 | 0.57 | 0.58 | 0.53 | 0.65 | 0.60 | 0.50 | 0.43 |
| Inventory Turnover | 1.03 | 1.03 | 1.34 | 1.36 | 1.20 | 1.31 | 1.42 | 1.77 | 1.96 | 1.66 | 2.10 |
| Days Sales Outstanding | — | 82.61 | 91.28 | 73.11 | 97.47 | 101.55 | 101.74 | 82.75 | 100.22 | 94.38 | 93.54 |
ALKS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Alkermes plc returns 0.5% to shareholders annually primarily through share buybacks. The earnings yield of 4.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.0% | 5.1% | 7.5% | 7.6% | — | — | — | — | — | — | — |
| FCF Yield | 8.1% | 10.2% | 8.3% | 7.5% | — | 1.9% | 1.3% | — | 0.7% | — | — |
| Buyback Yield | 0.5% | 0.7% | 4.1% | 0.6% | 0.4% | 0.4% | 0.2% | 0.3% | 0.4% | 0.2% | 0.2% |
| Total Shareholder Yield | 0.5% | 0.7% | 4.1% | 0.6% | 0.4% | 0.4% | 0.2% | 0.3% | 0.4% | 0.2% | 0.2% |
| Shares Outstanding | — | $169M | $169M | $170M | $164M | $161M | $159M | $157M | $155M | $153M | $151M |
Peer Comparison
Compare ALKS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ALKSYou | $6B | 24.7 | 17.5 | 12.4 | 86.3% | 17.2% | 14.7% | 18.9% | 0.2 |
 INVA | $2B | 6.8 | 5.5 | 8.6 | 72.3% | 38.5% | 29.1% | 16.8% | — |
 SUPN | $3B | -75.7 | 54.1 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.8 |
 ACAD | $4B | 15.8 | 13.6 | 23.1 | 91.5% | 24.1% | 38.9% | 45.2% | 0.2 |
 AXSM | $11B | -60.5 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 INTR | $3B | 18.7 | 12.4 | 3.9 | 47.4% | 12.4% | 10.9% | 4.8% | 8.4 |
 JAZZ | $14B | -39.1 | 24.0 | 11.1 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 TEVA | $42B | 30.3 | 17.8 | 36.9 | 51.8% | 12.5% | 20.7% | 7.7% | 5.5 |
 BHC | $2B | 13.1 | 6.4 | 2.1 | 60.9% | 21.3% | 588.2% | 8.2% | 6.1 |
 COLL | $1B | 21.1 | 4.5 | 3.6 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 AVPT | $2B | 68.5 | 44.5 | 27.2 | 74.1% | 7.9% | 9.4% | 1143.3% | 0.3 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See ALKS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALKS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALKS vs INVA
Side-by-side business, growth, and profitability comparison vs Innoviva, Inc..
Start ComparisonALKS — Frequently Asked Questions
Quick answers to the most common questions about buying ALKS stock.
What is Alkermes plc's P/E ratio?
Alkermes plc's current P/E ratio is 24.7x. The historical average is 42.7x. This places it at the 71th percentile of its historical range.
What is Alkermes plc's EV/EBITDA?
Alkermes plc's current EV/EBITDA is 17.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 23.9x.
What is Alkermes plc's ROE?
Alkermes plc's return on equity (ROE) is 14.7%. The historical average is -17.5%.
Is ALKS stock overvalued?
Based on historical data, Alkermes plc is trading at a P/E of 24.7x. This is at the 71th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Alkermes plc's profit margins?
Alkermes plc has 86.3% gross margin and 17.2% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Alkermes plc have?
Alkermes plc's Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.